Skip to main content
S&P 5007,673.52-0.58%DOW52,786.07-1.18%NASDAQ26,421.41-0.32%BTC$78,737.00-0.64%ETH$2,495.11+0.11%GOLD$4,398.60-0.91%OIL$94.62+1.71%
Smart Investors Daily
SU

NASDAQ · SUPN

Supernus Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

$42.43

Down-$1.10 (-2.53%)

Updated Sep 9, 2026, 2:53 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.6B
P/E ratio
-137.62
Dividend yield
0.00%
52-week range
$42.45 – $59.68
Volume
428.63K
Avg. volume
851.65K

Price performance

SUPN price history

1M range · 20 trading sessions · Daily adjusted prices

SUPN closed at $42.43 after 20 trading sessions, down 9.49% for the selected period.

Last close
$42.43
Period change
-9.49%
Period low
$42.43
Period high
$49.03
Daily close
View OHLC price history
SUPN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 8, 2026$43.56$43.56$42.32$42.43428.63K
Sep 4, 2026$43.66$44.11$43.43$43.53444.2K
Sep 3, 2026$44.56$44.56$43.16$43.97390.32K
Sep 2, 2026$44.42$45.045$43.67$44.03445.94K
Sep 1, 2026$44.35$44.7519$43.53$43.74757.78K
Aug 31, 2026$43.82$44.37$42.84$44.21535.72K
Aug 28, 2026$43.95$44.34$43.12$43.73487.93K
Aug 27, 2026$44.87$45.035$43.89$44.19464.95K
Aug 26, 2026$45.11$45.43$44.50$44.88499.68K
Aug 25, 2026$45.37$45.855$44.225$45.36496.06K
Aug 24, 2026$45.60$45.86$44.815$45.11495.51K
Aug 21, 2026$47.71$47.815$45.79$45.85748.89K
Aug 20, 2026$47.86$48.26$46.93$47.45646.85K
Aug 19, 2026$49.50$49.82$48.51$48.54797.22K
Aug 18, 2026$48.80$49.57$48.54$49.03592.24K
Aug 17, 2026$47.66$48.66$47.66$48.27536.73K
Aug 14, 2026$46.70$48.39$46.57$48.27331.73K
Aug 13, 2026$47.74$48.18$46.87$47.15667.87K
Aug 12, 2026$47.15$47.92$46.26$47.87667.32K
Aug 11, 2026$47.01$48.605$46.77$46.88669.69K

Latest SUPN news

The latest Smart Investors Daily articles mentioning SUPN.

Stock researchCompany · Overview

SUPN research

Overview

Company profile and research snapshot.

Company profile

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$64.00
Implied upside
—
Analysts
12
SUPN recent ratings
DateFirmRatingTarget
Jul 9, 2026Cantor FitzgeraldOverweight—
Dec 19, 2025StifelHold—
Oct 29, 2025B of A SecuritiesBuy—
Oct 23, 2025TD CowenBuy—
Oct 9, 2025Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Supernus Pharmaceuticals to Participate in September Investor Conferences

ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences: Cantor Global Healthcare ConferenceDate:Wednesday, September 9, 2026Fireside chat: 2:45 p.m. ETPlace: Waldorf Astoria, New York, NYWebcast Link: Here Wells Fargo Hea

Yahoo · Sep 2, 2026

3 Out-of-Favor Stocks We’re Skeptical Of

The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.

Yahoo · Aug 31, 2026

Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD

Chloe Kim is partnering with Supernus to highlight the importance of recognizing ADHD in adults and help empower individuals to work with their doctors to develop a tailored treatment plan.While ADHD is often associated with childhood, symptoms frequently persist into adulthood, and many people go undiagnosed until later in life.1Supported by years of clinical and real-world experience, Qelbree offers an established, non-controlled treatment option with approximately 3 million total prescription

Yahoo · Aug 25, 2026

3 Small-Cap Stocks with Open Questions

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By